Investigates PAX3-FOXO1 interactions affecting cancer treatment, suggesting new pathways.
C direct-detect nuclear magnetic resonance (NMR) spectroscopy to characterize acetylation in this system and identified a novel acetylation site corresponding to lysine 233 in endogenous FOXO1. In previous structural characterization of the endogenous FOXO1 DNA binding domain, local structure appears to prevent this site from becoming acetylated, suggesting that it becomes exposed in the context of the fusion protein. In addition, we demonstrate that the first bromodomain of the bromodomain and extraterminal domain-containing protein BRD4 binds to the acetylated region of interest and that this interaction is inhibited through the bromodomain and extraterminal domain inhibitor JQ1. These findings confer molecular mechanistic detail to previous observations that BRD4 and PAX3-FOXO1 colocalize at superenhancers in ARMS, adding to the growing body of literature exploring how BRD4 contacts cancer-relevant transcription factors in ways potentially relevant to the use of bromodomain and extraterminal domain inhibitors in cancer treatment.
No takes yet. Share an insight, caveat, or question.
Fraser et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: